Scholar Rock Holding (SRRK) Return on Capital Employed (2018 - 2026)
Scholar Rock Holding's quarterly Return on Capital Employed came in at 99.87% in Q1 2026, down 3280.0% year-on-year from 3.14% in Q1 2025, and up 8.46% quarter-over-quarter from 109.1% in Q4 2025.
Scholar Rock Holding has reported Return on Capital Employed for 9 years, with the latest figure at 99.87% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 3280.0% year-over-year to 99.87%; the trailing twelve-month figure through Mar 2026 stood at 99.87% (down 3280.0% YoY), and the FY2025 full-year result was 100.12%, down 2728.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 99.87%, up from 109.1% in the prior quarter.
- The five-year high for Return on Capital Employed was 34.62% in Q3 2022, with the low at 141.01% in Q3 2024.
- Average Return on Capital Employed over 5 years is 76.71%, with a median of 69.04% recorded in 2023.
- Year-over-year, Return on Capital Employed sank 7311 bps in 2024 and soared 2566 bps in 2025.
- Tracing SRRK's Return on Capital Employed over 5 years: stood at 39.77% in 2022, then plunged by 74 bps to 69.04% in 2023, then slumped by 30 bps to 89.99% in 2024, then decreased by 21 bps to 109.1% in 2025, then advanced by 8 bps to 99.87% in 2026.
- The last three Return on Capital Employed figures came in at 99.87% (Q1 2026), 109.1% (Q4 2025), and 115.35% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -99.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99.87% |
| Dec 31, 2025 | -109.10% |
| Sep 30, 2025 | -115.35% |
| Jun 30, 2025 | -99.99% |
| Mar 31, 2025 | -67.07% |
| Dec 31, 2024 | -89.99% |
| Sep 30, 2024 | -141.01% |
| Jun 30, 2024 | -97.91% |
| Mar 31, 2024 | -75.18% |
| Dec 31, 2023 | -69.04% |
| Sep 30, 2023 | -67.90% |
| Jun 30, 2023 | -59.48% |
| Mar 31, 2023 | -54.13% |
| Dec 31, 2022 | -39.77% |
| Sep 30, 2022 | -34.62% |
| Jun 30, 2022 | -40.19% |
| Mar 31, 2022 | -43.54% |
| Dec 31, 2021 | -54.79% |
| Sep 30, 2021 | -48.15% |
| Jun 30, 2021 | -38.38% |
| Mar 31, 2021 | -31.66% |
| Dec 31, 2020 | -37.24% |
| Sep 30, 2020 | -57.57% |
| Jun 30, 2020 | -49.91% |
| Mar 31, 2020 | -38.09% |
| Dec 31, 2019 | -34.16% |
| Sep 30, 2019 | -36.05% |
| Jun 30, 2019 | -34.16% |
| Mar 31, 2019 | -37.57% |
| Dec 31, 2018 | -44.45% |
| Sep 30, 2018 | -40.27% |